Indication
Andembry is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
Loading your page…
Loading your page…
Angioedemas, Hereditary
Marketing Authorisation Holder: CSL Behring GmbH
EMA Authorisation: 10/02/2025
INN: garadacimab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Andembry: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.